Biblio

Author Title [ Type

] Year

Filters: Author is Qiu, Lugui [Clear All Filters]

Journal Article

Zeng D, Fang Y, Fei Y, Liang R, Ye H, Liang Y, Sun X, Wang M, Huang H, Qiu L, et al. Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE. Int J Cancer. 2023.

Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, et al. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. N Engl J Med. 2014;371(10):906-917.

Xu J, Yan W, Fan H, Liu J, Li L, Du C, Deng S, Sui W, Xu Y, Qiu L, et al. Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation. Ann Hematol. 2023.

Zhou L, Fu W, Wu S, Xu K, Qiu L, Xu Y, Yan X, Zhang Q, Zhang M, Wang L, et al. Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study. Br J Haematol. 2023.

Liu W, Zou H, Chen L, Huang W, Lv R, Xu Y, Liu H, Shi Y, Wang K, Wang Y, et al. Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma. J Immunother Cancer. 2024;12(4).

Liu J, Yan W, Fan H, Xu J, Li L, Du C, Mao X, Yan Y, Xu Y, Sui W, et al. Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment. Cancer Res Commun. 2023;3(9):1770-1780.

Liu W, Ji J, Zou D, Cao Y, Xu Y, Zhou J, Gao S, Wang F, Chen W, Du J, et al. Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China. Bone Marrow Transplant. 2022.

Du C, Li L, Fan H, Mao X, Liu J, Xu Y, Sui W, Deng S, Li C, Zhao J, et al. The age-dependent changes in risk weights of the prognostic factors for multiple myeloma. Hematology. 2023;28(1):2258686.